Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457891 | 0.83 | BLM (0.47) | HPGDNPC1RAB9ASMN1; SMN2BLM | |
| SCHEMBL12659250 | 0.83 | HPGD (0.44) | HPGDNPC1RAB9ASMN1; SMN2BLM | |
| SCHEMBL10767808 | 0.82 | LMNA (0.42) | NPC1RAB9AMAOBBLMESR1 | |
| SCHEMBL9626513 | 0.82 | RIPK1 (0.47) | HPGDSMN1; SMN2MAOBBLML3MBTL1 | |
| SCHEMBL5728540 | 0.82 | CES2 (0.41) | HPGDBLMMAPTESR1ALDH1A1 | |
| SCHEMBL10383881 | 0.82 | SLC6A4 (0.53) | NPC1RAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL2442200 | 0.82 | EPHX2 (0.47) | LMNA | |
| SCHEMBL6552350 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5729103 | 0.80 | PPARA (0.49) | BLMESR1THRATHRBTDP1 | |
| SCHEMBL2444598 | 0.80 | HPGD (0.46) | HPGDNPC1RAB9ASMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157168-A1 | PREVENTION OF GASTRIC ULCER BY CARBON MONOXIDE | ALFAMA-INVESTIGAÇÃO E DESENVOLVIMENTO DE PRODUTOS FARMACÊUTICOS LDA (PT) | 2017-06-08 | — | — | US | disclosed |
| US-20140212514-A1 | PREVENTION OF GASTRIC ULCER BY CARBON MONOXIDE | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUTOS FARMACEUTICOS, LDA. (PT) | 2014-07-31 | — | — | US | disclosed |
| US-7968605-B2 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. (PT) | 2011-06-28 | — | — | US | disclosed |
| US-20110038955-A1 | PREVENTION OF GASTRIC ULCER BY CARBON MONOXIDE | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUTOS FARMACEUTICOS, LDA. (PT) | 2011-02-17 | — | — | US | disclosed |
| US-20100196516-A1 | TREATMENT OF INFECTIONS BY CARBON MONOXIDE | ALFAMA-Investigacao e Desenvolvimento de produtos Farmaceuticos, Lda (PT) | 2010-08-05 | — | — | US | disclosed |
| US-20080026984-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUCTOS FARMACEUTICOS LDA (PT) | 2008-01-31 | — | — | US | disclosed |
| US-20070219120-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUCTOS FARMACEUTICOS LDA (PT) | 2007-09-20 | — | — | US | disclosed |
| US-5502233-A | PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
| EP-0572440-B1 | SUBSTITUDED PYRIDYLPYRIMIDINES, THEIR PREPARATION AND THEIR USE, AS WELL AS NEW INTERMEDIATE PRODUCTS | BAYER AG (DE) | 1995-08-02 | — | — | EP | disclosed |
| US-5416088-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-16 | — | — | US | disclosed |
| EP-0572440-A1 | SUBSTITUDED PYRIDYLPYRIMIDINES, THEIR PREPARATION AND THEIR USE, AS WELL AS NEW INTERMEDIATE PRODUCTS. | BAYER AG (DE) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014726-A1 | SUBSTITUDED PYRIDYLPYRIMIDINES, THEIR PREPARATION AND THEIR USE, AS WELL AS NEW INTERMEDIATE PRODUCTS | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038955-A1 | PREVENTION OF GASTRIC ULCER BY CARBON MONOXIDE | PTGS1, PTGS2, NOS2 | HPGD 34/4885NPC1 2556/4885RAB9A 2933/4885 |
| US-20080026984-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | MPO, TNF, AOX1 | HPGD 135/4885NPC1 1245/4885RAB9A 3850/4885 |
| US-20170157168-A1 | PREVENTION OF GASTRIC ULCER BY CARBON MONOXIDE | PTGS1, PTGS2, NOS2 | HPGD 34/4885NPC1 2556/4885RAB9A 2933/4885 |
| US-20070219120-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | MPO, TNF, AOX1 | HPGD 135/4885NPC1 1245/4885RAB9A 3850/4885 |
| US-20100196516-A1 | TREATMENT OF INFECTIONS BY CARBON MONOXIDE | MB, IFNG, CORO1C | HPGD 946/4885NPC1 1113/4885RAB9A 3211/4885 |
| US-20140212514-A1 | PREVENTION OF GASTRIC ULCER BY CARBON MONOXIDE | PTGS1, PTGS2, NOS2 | HPGD 34/4885NPC1 2556/4885RAB9A 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.